Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

Ischemic Stroke l: Introduction

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.

Ischemic Stroke ll: Pathophysiology

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...

Ischemic Heart Disease: Overview

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...

Transient Ischemic Attack l: Introduction

Transient Ischemic Attack l: Introduction

A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Conserved Transcriptional Response to Adversity and Stress: Historical Roots, Neurobiological Mechanisms, and Yoga Interventions.

The primary care companion for CNS disorders·2026

Same author

Dealing with oral anticoagulants in stroke patients: A narrative review based on current practice guidelines.

Brain circulation·2026

Same author

Clinico-Etiological Profile of Young-Onset Dementia From a Tertiary Care Center in Northern India.

Cureus·2025

Same author

Evaluation of postoperative pain in patients using 8.25 % sodium hypochlorite compared with 5.25 % sodium hypochlorite using sonic and ultrasonic activation methods after single visit root canal treatment: an in-vivo study.

Journal of oral biology and craniofacial research·2025

Same author

Silent rupture: The hidden danger of gastric perforation in paediatric blunt trauma: A case report.

Bioinformation·2025

Same author

Chronic nonspecific multiple-sites pain [CNMSP] of unknown etiology: Biopsychosocial method of evaluation for the primary care level.

Journal of family medicine and primary care·2024

Search research articles

Related Experiment Video

Updated: May 10, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Edaravone - citicoline comparative study in acute ischemic stroke (ECCS-AIS).

Manish Mitta¹, Deepak Goel, Krishan K Bansal

¹Department of General Medicine, HIHT University, Swami Ram Nagar, Doiwala, Dehradun.

The Journal of the Association of Physicians of India

|June 18, 2013

Summary

This summary is machine-generated.

Edaravone demonstrated superior neuroprotection in acute ischemic stroke (AIS) patients compared to Citicoline and no treatment. This study highlights Edaravone

More Related Videos

AAV Systems and Mouse Models for Investigating Ectopic Expression of Neurod1 in Transduced Cells at Subacute and Chronic Times Post-Ischemic Stroke

AAV Systems and Mouse Models for Investigating Ectopic Expression of Neurod1 in Transduced Cells at Subacute and Chronic Times Post-Ischemic Stroke

Published on: November 29, 2024

Related Experiment Videos

Last Updated: May 10, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

AAV Systems and Mouse Models for Investigating Ectopic Expression of Neurod1 in Transduced Cells at Subacute and Chronic Times Post-Ischemic Stroke

AAV Systems and Mouse Models for Investigating Ectopic Expression of Neurod1 in Transduced Cells at Subacute and Chronic Times Post-Ischemic Stroke

Published on: November 29, 2024

Area of Science:

Neurology
Pharmacology

Background:

Acute ischemic stroke (AIS) is a leading cause of disability.
Edaravone and Citicoline are emerging neuroprotective agents for AIS.
Comparative studies on these agents under identical protocols are lacking.

Purpose of the Study:

To compare the efficacy of Edaravone versus Citicoline in AIS patients.
To evaluate neuroprotection in AIS using standardized treatment protocols.

Main Methods:

Randomized controlled trial involving adult AIS patients presenting within 24 hours.
Treatment groups: Edaravone (E), Citicoline (C), and control (N).
Outcomes assessed using Modified Rankin Scale (MRS) and NIH Stroke Scale (NIHSS) at 3 months; analyzed with ANOVA t-test.

Main Results:

Edaravone group showed significantly lower mean MRS and NIHSS scores at 3 months (p=0.000).
In moderate to severe stroke patients, Edaravone group had significantly better outcomes (mean 4.46) compared to Citicoline (10.28) and control (9.38) groups (p=0.00).
Higher proportion of patients in Edaravone group achieved better functional recovery.

Conclusions:

Edaravone significantly improves neurological outcomes in acute ischemic stroke patients at 3 months.
The neuroprotective role of Citicoline in AIS remains inconclusive.
Edaravone represents a promising therapeutic option for improving recovery post-AIS.